Navigation Links
Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
Date:4/17/2009

SAN DIEGO, April 17 /PRNewswire/ -- Cylene Pharmaceuticals announced today that it will be presenting new data on recent advances of its small molecule anticancer agents during a symposium and several poster presentations at the American Association for Cancer Research (AACR) annual meeting, to be held on April 18-22 in Denver, Colorado.

Cylene scientists will unveil the first public description of CX-4945, a first-in-class oral inhibitor of protein kinase CK2. CK2 overexpression is well documented in many cancers and represents a previously unexploited molecular target. CX-4945 is a potent, selective inhibitor of CK2 and modulates key survival pathways in cancer cells. CX-4945, which has broad therapeutic potential in common cancers as well as in niche indications, has advanced rapidly into Phase I clinical trials.

The oral symposium will address the identification of pathway-specific biomarkers, while the posters will address the discovery and characterization of CX-4945 and the ability of CX-4945 to inhibit CK2-driven HIF-1alpha transcription and angiogenesis in hypoxia. In a separate poster, Dr. John Lim will describe the advancement of quarfloxin (CX-3543) into Phase II clinical trials in carcinoid/neuroendocrine tumors. The presentation schedule is:

Sunday, April 19, 2009: 8:00 AM CX-4945, a small molecule inhibitor of CK2, inhibits angiogenesis by affecting the vascular endothelium and suppressing hypoxia-activated HIF-1alpha transcription - Tumor Biology 2, Abstract 145

Tuesday, April 21, 2009: 8:00 AM Quarfloxin phase I clinical data and scientific findings supporting the selection of carcinoid/neuroendocrine tumors as the phase II indication - Clinical Research 12, Abstract 3599

Tuesday, April 21, 2009: 1:00 PM Discovery and characterization of CX-4945 a selective orally bioavailable small molecule inhibitor of protein kinase CK2: Phase I initiated - Experimental and Molecular Therapeutics 34, Abstract 4660

Tuesday, April 21, 2009: 2:00 PM CX-4945, a potent and selective inhibitor of CK2, modulates PI3K/AKT signaling and phosphorylation of p21 in vitro and in vivo: Implications for biomarker development - Experimental and Molecular Therapeutics 37, Minisymposium, Abstract 4768

About Cylene Pharmaceuticals, Inc.

Cylene Pharmaceuticals is a biotech pharmaceutical company dedicated to the discovery, development and commercialization of targeted small-molecule drugs to treat life-threatening cancers. Cylene has created a diverse portfolio of product candidates, including novel inhibitors of cancer-linked serine/threonine protein kinases, as well as innovative nucleolus targeting agents (NTAs). More information can be found at www.cylenepharma.com.

Cylene cautions you that statements included in this press release that are not a description of historical facts, including implied statements relating to future outcomes of clinical trials, may be forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Cylene's business including, without limitation, risks related to difficulties or delays in testing, obtaining regulatory approval for, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. All forward-looking statements are qualified in their entirety by this cautionary statement and Cylene undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE Cylene Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
2. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
3. Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research
4. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
5. Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
6. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
7. NewCardio Leadership to Present Two Abstracts at ISCE Conference
8. RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009
9. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
10. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
11. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- Halo Labs announces the European launch of their new low ... MIBio 2017 in Cambridge, U.K on October ... biopharmaceutical samples with unprecedented speed and sensitivity while using far less ... Imaging. ... analysis system ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
Breaking Medicine News(10 mins):